Top 10 Companies in the (S)-1-(3-Chlorophenyl)-ethylamine (CAS 68297-62-1) Market (2026): Market Leaders Powering Global Growth

MARKET INSIGHTS

Global (S)-1-(3-Chlorophenyl)-ethylamine (CAS 68297-62-1) market size was valued at USD 28.4 million in 2025. The market is forecasted to grow from USD 30.1 million in 2026 to USD 54.7 million by 2034, exhibiting a CAGR of 6.9% during the forecast period.

(S)-1-(3‑Chlorophenyl)-ethylamine (CAS 68297-62-1) is a chiral amine characterized by a single stereocenter bearing an amino group on a 3‑chlorophenyl‑substituted ethyl backbone. It serves as a critical building block and resolving agent in asymmetric synthesis, widely employed in the pharmaceutical industry for the production of enantiomerically pure active pharmaceutical ingredients (APIs). Its high optical purity and well‑defined stereochemistry make it particularly valuable in the synthesis of central nervous system (CNS) drugs, agrochemicals, and other fine chemical intermediates.

The market is witnessing steady growth driven by expanding global demand for chiral intermediates, increasing adoption of asymmetric synthesis techniques, and the pharmaceutical industry’s shift toward enantiomerically pure drug formulations. Tightening regulatory requirements around racemic drug approvals reinforce demand for high‑purity chiral amines such as (S)-1‑(3‑Chlorophenyl)-ethylamine. Key suppliers include Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Alfa Aesar, among other specialty chemical manufacturers.

(S)-1-(3‑Chlorophenyl)-ethylamine (CAS 68297-62-1) Market – View in Detailed Research Report

Top 10 Companies in the (S)-1-(3‑Chlorophenyl)-ethylamine (CAS 68297-62-1) Market

1. MilliporeSigma (Merck KGaA)

Headquarters: Germany / United States
Key Offering: High‑purity chiral intermediates for API synthesis

MilliporeSigma leverages its extensive GMP‑compliant infrastructure to supply chiral amines with enantiomeric excess exceeding 99%. The company’s integrated analytical platform ensures traceable purity data, a critical requirement for pharmaceutical clients. Its global distribution network supports rapid delivery to contract research organizations and pharma manufacturers alike.

Sustainability & Growth Initiatives:

• Investment in green chemistry routes for chiral synthesis
• Expansion of low‑energy, solvent‑reduction processes
• Commitment to ISO 14001 environmental management

2. Tokyo Chemical Industry Co., Ltd. (TCI)

Headquarters: Japan
Key Offering: Custom‑grade chiral amines and resolution services

TCI provides tailored synthesis pathways, enabling clients to achieve specific optical purity targets. Its proprietary chiral resolution techniques reduce waste and improve atom economy, aligning with industry demands for cost‑effective production.

Sustainability & Growth Initiatives:

• Development of enzymatic resolution processes
• Adoption of renewable feedstocks for precursor synthesis
• Carbon‑neutral production targets by 2030

3. Fluorochem Ltd.

Headquarters: United Kingdom
Key Offering: High‑purity chiral intermediates for agrochemical and pharmaceutical sectors

Fluorochem’s focus on precision chemistry allows it to supply chiral amines with stringent ee specifications. The company maintains a robust quality management system that satisfies ICH Q7 requirements, ensuring consistent batch performance.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop solvent recycling
• Partnerships with academic institutions for catalyst development
• Reduction of hazardous waste streams by 25% over five years

4. Combi‑Blocks Inc.

Headquarters: United States
Key Offering: Custom synthesis and scale‑up services for chiral amines

Combi‑Blocks specializes in rapid scale‑up of chiral intermediates, providing end‑to‑end solutions from laboratory synthesis to commercial production. Its modular process design enables flexible batch sizing, catering to both early‑stage research and large‑volume API manufacturing.

Sustainability & Growth Initiatives:

• Investments in biocatalytic synthesis platforms
• Use of biodegradable polymers in packaging
• Energy efficiency upgrades across facilities

5. Ark Pharm, Inc.

Headquarters: United States
Key Offering: High‑purity chiral building blocks for CNS drug development

Ark Pharm’s portfolio includes a range of arylethylamine scaffolds, with (S)-1‑(3‑Chlorophenyl)-ethylamine positioned as a key intermediate for CNS candidates. The company’s rigorous quality controls and rapid turnaround times make it a preferred partner for biotech firms.

Sustainability & Growth Initiatives:

• Adoption of aqueous phase synthesis to reduce solvent use
• Collaboration with research institutions on green catalysts
• Carbon footprint monitoring and reporting

6. Enamine Ltd.

Headquarters: Ukraine
Key Offering: Custom chiral amines and resolution services

Enamine offers a flexible synthesis platform that can accommodate a wide range of optical purity requirements. Its integrated quality assurance processes provide detailed analytical reports, supporting regulatory submissions.

Sustainability & Growth Initiatives:

• Development of solvent‑free reaction protocols
• Use of renewable energy sources for production
• Waste minimization through process optimization

7. Zhengzhou Alfa Chemical Co., Ltd.

Headquarters: China
Key Offering: High‑purity chiral intermediates for API synthesis

Zhengzhou Alfa Chemical combines large‑scale manufacturing capacity with stringent quality controls. The company’s focus on high‑purity grades aligns with the needs of pharmaceutical clients seeking consistent batch performance.

Sustainability & Growth Initiatives:

• Implementation of energy‑efficient production lines
• Use of recycled water in downstream processing
• Certification of environmental management systems

8. Hangzhou Keying Chem Co., Ltd.

Headquarters: China
Key Offering: Custom synthesis and resolution of chiral amines

Hangzhou Keying Chem provides tailored synthesis solutions, enabling clients to achieve specific enantiomeric excess targets. The company’s investment in advanced analytical instrumentation ensures high‑quality data for regulatory submissions.

Sustainability & Growth Initiatives:

• Adoption of continuous flow synthesis technologies
• Reduction of hazardous waste by 30% through process redesign
• Collaboration with local universities for catalyst research

9. Biosynth AG

Headquarters: Switzerland
Key Offering: High‑purity chiral intermediates and custom synthesis

Biosynth AG focuses on precision chemistry and offers a suite of chiral amines for pharmaceutical applications. Its robust GMP compliance and comprehensive documentation support regulatory approvals.

Sustainability & Growth Initiatives:

• Investment in green chemistry research programs
• Use of renewable energy in manufacturing facilities
• Implementation of circular waste management practices

10. Alfa Aesar

Headquarters: United States
Key Offering: Research‑grade chiral amines for academic and industrial use

Alfa Aesar supplies a range of chiral intermediates, including (S)-1‑(3‑Chlorophenyl)-ethylamine, to research institutions and small‑scale manufacturers. Its catalog offers flexible ordering options and detailed product specifications.

Sustainability & Growth Initiatives:

• Development of solvent‑free synthesis routes
• Use of biodegradable packaging materials
• Commitment to reducing greenhouse gas emissions by 20% by 2030

Download FREE Sample Report: (S)-1-(3‑Chlorophenyl)-ethylamine (CAS 68297-62-1) Market – View in Detailed Research Report

Get Full Report: (S)-1-(3‑Chlorophenyl)-ethylamine (CAS 68297-62-1) Market – View in Detailed Research Report

Outlook

The forecast period is shaped by a continued focus on single‑enantiomer drug development, particularly within the CNS and cardiovascular therapeutic areas. The regulatory environment, which increasingly demands precise stereochemical characterization, will sustain demand for high‑purity chiral intermediates. Companies that can combine robust GMP compliance with cost‑effective, scalable synthesis will be best positioned to capture market share.

Future Trends

Emerging developments in biocatalytic and enzymatic synthesis are expected to reduce reliance on traditional metal‑catalyzed processes, offering lower environmental impact and improved selectivity. Additionally, the rise of contract development and manufacturing organizations (CDMOs) in early‑stage drug discovery will increase the need for custom synthesis services capable of delivering defined optical purities at scale. Finally, the growing interest in agrochemical applications of chiral amines may open new avenues for market expansion beyond the pharmaceutical domain.